
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc. demonstrates a promising outlook due to favorable biomarker and safety data surrounding its lead candidate, PMN310, which supports its mechanistic advantage and potential for clinical advancement. The company's innovative platform has successfully identified novel therapeutic targets, exemplified by PMN267's dual selectivity profile, which may enhance efficacy and safety across a range of neurodegenerative diseases. Additionally, the absence of adverse events such as ARIA in PMN310 strengthens confidence in its safety profile compared to existing treatments, providing multiple opportunities for successful clinical outcomes and financial upside.
Bears say
ProMIS Neurosciences's financial outlook appears negative due to a reported net loss of $11.6 million, translating to a loss of $0.24 per share in the third quarter of 2025, indicating ongoing financial struggles. Additionally, challenges related to potential partnership risks, an anticipated slow market uptake attributed to heightened competition, and risks of near-term dilution further compound the company's fiscal uncertainties. The company's historical inability to achieve profitability, combined with evidence of previously failed therapies in targeting toxic Aβ oligomers, raises concerns about the viability of its core therapeutic approaches in a competitive biotechnology landscape.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares